Clinical benefit of cancer drugs approved in Switzerland 2010–2019
<h4>Background</h4> It is unknown to what extent cancer drugs approved in Switzerland by the Swissmedic fulfil criteria of clinical benefit according to the European Society of Medical Oncology Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS), the American Society of Clinical...
Main Authors: | Roman Adam, Ariadna Tibau, Consolación Molto Valiente, Boštjan Šeruga, Alberto Ocaña, Eitan Amir, Arnoud J. Templeton |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187080/?tool=EBI |
Similar Items
-
Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
by: Roman Adam, et al.
Published: (2022-01-01) -
Extended adjuvant tamoxifen for early breast cancer: a meta-analysis.
by: Mustafa Al-Mubarak, et al.
Published: (2014-01-01) -
Association between control group therapy and magnitude of clinical benefit of cancer drugs
by: Consolacion Molto, et al.
Published: (2022-12-01) -
Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade
by: Domen Ribnikar, et al.
Published: (2021-05-01) -
Associations between safety, tolerability, and toxicity and the reporting of health‐related quality of life in phase III randomized trials in common solid tumors
by: Ramy R. Saleh, et al.
Published: (2020-11-01)